Arginase in retinopathy.

Area of Science:

• Ophthalmology
• Biochemistry
• Molecular Biology

Background:

• Ischemic retinopathies are a leading cause of blindness, characterized by early neurovascular dysfunction.
• Current treatments for retinopathy, like anti-VEGF injections and laser photocoagulation, target later disease stages and have limitations.
• These therapies do not address early disease or promote tissue repair.

Purpose of the Study:

• To review the role of the ureahydrolase enzyme arginase as a potential therapeutic target for ischemic retinopathy.
• To explore how arginase activity contributes to the pathogenesis of retinopathy.

Main Methods:

• Review of existing studies on arginase activity in the context of ischemic retinopathies.
• Analysis of the metabolic pathways involving arginase, l-arginine, and nitric oxide synthase (NOS).
• Examination of the roles of arginase isoforms (AI and AII) in different retinopathy models.

Main Results:

• Increased arginase expression/activity is linked to neurovascular injury in retinopathy.
• Excessive arginase reduces l-arginine availability for NOS, leading to uncoupling and superoxide production.
• Arginase activity contributes to oxidative stress, DNA damage, and cellular injury in the retina.

Conclusions:

• The arginase pathway activation contributes to neurovascular injury in retinopathy by reducing nitric oxide and increasing oxidative stress.
• Arginase I (AI) is implicated in hyperglycemia-induced vascular endothelial cell dysfunction.
• Arginase II (AII) is involved in neurovascular dysfunction and cell death following hyperoxia.